ANGO
AngioDynamics, Inc.
ANGO's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ANGO overall, supported by stronger fundamentals and stronger modeled upside.
ANGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Strong |
ANGO's balance sheet is currently strong, and its revenue and cash flow are stable, but its profitability is under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ANGO PE Valuation
ANGO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ANGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect ANGO's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ANGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.79 | -$0.01 |
| Q2 2026 | -$0.88 | -$0.05 |
| Q1 2026 | -$0.75 | +$0.28 |
| Q4 2025 | -$0.67 | +$4.92 |
| Q3 2025 | -$0.78 | +$5.27 |
| Q2 2025 | -$0.83 | +$3.76 |
| Q1 2025 | -$1.03 | +$3.76 |
| Q4 2024 | -$5.59 | -$5.23 |
ANGO is still losing money, but far less than before: $0.79 per share over the past year, against $6.05 at its worst in mid-2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ANGO on earnings quality, reporting a profit while its opponent remains loss making.
ANGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $80.9M | +6.9% |
| Q2 2026 | $86.6M | +8% |
| Q1 2026 | $78.4M | +8.9% |
| Q4 2025 | $79.4M | +9% |
| Q3 2025 | $75.7M | +12% |
| Q2 2025 | $80.2M | +13% |
| Q1 2025 | $72M | -4.2% |
| Q4 2024 | $72.8M | -7.9% |
ANGO's revenue has grown year over year for six quarters in a row: $81M last quarter, up 6.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9% | +5.1 points |
| Q2 2026 | -12% | -4.5 points |
| Q1 2026 | -17% | -2.7 points |
| Q4 2025 | -7.7% | +7.5 points |
| Q3 2025 | -14% | +5.3 points |
| Q2 2025 | -7.2% | +13 points |
| Q1 2025 | -14% | +252 points |
| Q4 2024 | -15% | +1.4 points |
ANGO's operating margin was −9% last quarter, up 5.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ANGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ANGO on profitability, with a higher operating margin.
ANGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.7M | +$936K |
| Q2 2026 | $17M | -5.5% |
| Q1 2026 | -$4.1M | +$10.8M |
| Q4 2025 | $4.2M | +153% |
| Q3 2025 | -$16.6M | +$2.7M |
| Q2 2025 | $18M | +307% |
| Q1 2025 | -$15M | -$1.8M |
| Q4 2024 | $1.7M | -64% |
ANGO's free cash flow has turned positive after two years mostly in the red: $1M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ANGO on cash flow, with more consistent year-over-year improvement.
ANGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +496K shares |
| 1 year | +2.1% | +848K shares |
| 3 years | +5.1% | +2.1M shares |
| 5 years | +8.5% | +3.3M shares |
| Available history | +11% | +4M shares |
ANGO has 42M diluted shares, up 2.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $1.1M |
| Q3 2024 | $552,000 |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ANGO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ANGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -2.9x | Net Cash |
| Q3 2023 | -2.1x | Net Cash |
| Q2 2022 | -32.8x | Net Cash |
| Q4 2019 | -6.1x | Net Cash |
ANGO has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ANGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 22.6 | Neutral |
ANGO's weekly RSI is 43 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ANGO PE vs Healthcare Sector
| Metric | ANGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANGO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ANGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.7 | 5.5% below |
| 20 week MA | $13.9 | 14% below |
| 50 week MA | $12.4 | 3.4% below |
| 100 week MA | $11.3 | 5.7% above |
| 200 week MA | $9.60 | 25% above |
ANGO has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 25% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ANGO on trend strength, trading above more of its moving averages.
ANGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.0 | $14.1 | -11% |
| 2021 | $14.1 | $28.2 | +100% |
| 2022 | $28.2 | $13.3 | -53% |
| 2023 | $13.3 | $7.84 | -41% |
| 2024 | $7.84 | $8.91 | +14% |
| 2025 | $8.91 | $13.1 | +47% |
| 2026 YTD | $13.1 | $12.0 | -8.5% |
ANGO has finished lower in three of the last six years. It's down 8.5% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ANGO on returns for 2026, with the stronger performance.